Volume 2, Issue 10
Effect Of Roflumilast On Morphological Changes In Mucous Membrane Of Bronchi In Patients With Severe Chronic Obstructive Pulmonary Disease
Authors: Iryna Savelikhina; Olena Deltsova; Vasyl Pertsovych; Sergiy Gerashchenko; Oleksandra Marchuk; Mykola Ostrovskyy
Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity both in developed and developing countries that is mainly characterized by progressive and not fully reversible airflow limitation. Roflumilast is a first-in-class oral once-daily phosphodiesterase type-4 inhibitor licensed for the treatment of COPD. Remodeling of respiratory tracts is a pathologic process observed at chronic inflammatory and obstructive diseases of respiratory tracts, and it is prescribed on the background of a COPD maintance treatment. For 9 people with severe COPD before treatment and after 30 and 180 days treatment with roflumilast were performed biopsies of the mucous membrane of the bronchi. Verification of the diagnosis and its formulation confirmed with the orders of Ministry of Health of Ukraine № 128 from 19.03.2007. "On approval of clinical protocols of medical care in the specialty pulmonology".
Download Full Article: Click Here
Support Us
If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.
